Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

NCT07741630 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07741630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07741630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer
Lead sponsor
Peking University Third Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 15, 2026
Completion date
April 30, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

proc